

Effectiveness of Mebeverine in patients with post-cholecystectomy gastrointestinal spasm: Results of prospective observational program "odyssey"

Kazan Federal University, 420008, Kremlevskaya 18, Kazan, Russia

Abstract

© 2018 Media Sphera Publishing Group. All rights reserved. Aim: to assess the effectiveness of mebeverine 200 mg BID in patients with post-cholecystectomy gastrointestinal spasm not requiring surgical treatment. Materials and methods. 218 patients were included in 16 clinical centers in 14 cities in Russia. All patients had post-cholecystectomy gastrointestinal spasms, not requiring surgical treatment and received mebeverine (Duspatalin®) 200 mg BID. The observational assessment period lasted from the moment of their inclusion into the study up to 6 weeks post inclusion. The therapy results were evaluated using visual analog scales (GPA and 11-point numeric rating scale) by patient self-assessment of the dynamics of spasm/discomfort and other postcholecystectomic gastrointestinal symptoms after 2 and 6 weeks of treatment. Gastrointestinal Quality of Life Index (GIQLI) was used to assess patient quality of life. Results and discussion. All 218 patients completed the 2-week mebeverine treatment course, 101 of them finished the 6-week course ("prolonged population"). Significant positive changes in the relief of abdominal pain and dyspepsia were noted as well as normalization of stool frequency and consistency. A more marked change in values was observed during prolonged (up to 6 weeks) therapy. Both 2-week and 6-week mebeverine courses led to a normalization of patient quality of life. After 6 week therapy, an effect of mebeverine on the quality of life 91% of patients was observed comparable to cholecystectomy itself, specially related to the quality of life subscore 'symptoms'. Conclusion. The results of our study demonstrate that mebeverine (Duspatalin®) therapy leads to an effective elimination of clinical symptoms associated with post-cholecystectomy GI-spasm disorders, like abdominal pain, symptoms of dyspepsia and stool disorders. A more marked change in values was observed during prolonged (up to 6 weeks) therapy.

<http://dx.doi.org/10.26442/terarkh201890840-47>

Keywords

"Odyssey", Abdominal pain, Cholecystectomy, Gallstone disease (GD), Mebeverine, PCS, Post-cholecystectomy spasm and disorders

References

- [1] Ivashkin VT, Maev IV, Baranskaya EK, et al. Recommendations of the Russian gastroenterological association for the diagnosis and treatment of cholelithiasis. Rossiyskiy Zhurnal Gastroenterologii, Hepatologii, Koloproktologii. 2016;26(3):64-80 (In Russ.)

- [2] EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. *J Hepatol.* 2016;65(1):146-181.
- [3] Hauser SC, ed. *Mayo Clinic gastroenterology and hepatology board review.* 5 ed. oxford University Press; 2015. 425 p.
- [4] Wang DQ, Afdhal NH. Gallstone Disease. In: Feldman M, Friedman LS, Brandt LJ, eds. *Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management.* 10 ed. Elsevier; 2015.
- [5] Ros E, Zambon D. Postcholecystectomy symptoms. A prospective study of gall stone patients before and two years after surgery. *Gut.* 1987;28(11):1500-1504.
- [6] Finan KR, Leeth RR, Whitley BM, Klapow JC, Hawn MT. Improvement in gastrointestinal symptoms and quality of life after cholecystectomy. *Am J Surg.* 2006;192(2):196-202.
- [7] Weinert CR, Arnett D, Jacobs D Jr, Kane RL. Relationship between persistence of abdominal symptoms and successful outcome after cholecystectomy. *Arch Intern Med.* 2000;160(7):989-995.
- [8] Eremina EYu. Zhelchnokamennaya bolezni': do i posle kholetsistektomii. Metodicheskie ukazaniya dlya vrachey [Gallstone disease: before and after cholecystectomy. Methodical instructions for doctors]. Saransk; 2014 (In Russ.)
- [9] Arutyunov GP, Martynov AI, Spasskiy AA. *Rukovodstvo po vnutrenney meditsine* [Guide to Internal Medicine]. Moscow; 2015 (In Russ.)
- [10] Kennedy TM, Jones RH. Epidemiology of cholecystectomy and irritable bowel syndrome in a UK population. *Br J Surg.* 2000;87:1658-1663.
- [11] Kirk G, Kennedy R, McKie L, et al. Preoperative symptoms of irritable bowel syndrome predict poor outcome after laparoscopic cholecystectomy. *Surg Endosc.* 2011;25:3379-3384.
- [12] Yamada T, ed. *Textbook of gastroenterology.* 2 ed. Philadelphia: Lippincott; 1995.
- [13] Zhou PH, Liu FL, Yao LQ, Qin XY. Endoscopic diagnosis and treatment of postcholecystectomy syndrome. *Hepatobil Pancreat Dis Int.* 2003;2:117-120.
- [14] Jaunoo SS, Mohandas S, Almond LM. Postcholecystectomy syndrome (PCS). *Int J Surg.* 2010;8(1):15-17.
- [15] Minushkin ON. Syndrome after cholecystectomy in the practice of the therapist and gastroenterologist. *Lechashchiy Vrach.* 2015;(2):40-46 (In Russ.)
- [16] Jensen SW. Postcholecystectomy Syndrome Clinical Presentation. In.: MedScape. 2016. Available from: <https://emedicine.medscape.com/article/192761-clinical>
- [17] Filip M, Saftoiu A, Popescu C, Gheonea DI, Iordache S, Sandulescu L, Ciurea T. Postcholecystectomy Syndrome - an Algorithmic Approach. *J Gastrointestin Liv Dis.* 2009;18(1):67-71.
- [18] Trukhan DI, Viktorova IA, Lyalyukova EA. Bolezni zhelchnogo puzrya i zhelchevyvodyashchikh putey [Diseases of the gall bladder and biliary tracts]. St. Petersburg: SpetsLit; 2011. 127 p. (In Russ.)
- [19] Il'chenko AA. Bolezni zhelchnogo puzrya i zhelchnykh putey: Rukovodstvo dlya vrachey [Diseases of the gallbladder and biliary tract: A guide for doctors]. 2 ed. Moscow: Meditsinskoe informatsionnoe agentstvo; 2011. 880 p. (In Russ.)
- [20] Il'chenko AA, Bystrovskaya EV. The experience of using Duspatalin in functional disorders of the sphincter of oddi in patients who underwent cholecystectomy. *Eksperimental'naya i Klinicheskaya Gastroenterologiya.* 2002;(4):21-22 (In Russ.)
- [21] Movchun VA, Ardatskaya MD, Isakova oV, Lipnitskiy EM Efficacy of duspatalin in the treatment and prevention of postcholecystectomy syndrome. *Vestnik Rossiyskoy Akademii Meditsinskikh Nauk.* 2011;(1):7-11 (In Russ.)
- [22] Drossman DA. The functional gastrointestinal disorders and the Rome III process. *Gastroenterology.* 2006 Apr;130(5):1377-1390.
- [23] Shi HY1, Lee KT, Lee HH, Uen YH, et al. The minimal clinically important difference in the Gastrointestinal Quality-of-Life Index after cholecystectomy. *Surg Endosc.* 2009;23(12):2708-2712.
- [24] Lamberts MP, Lugtenberg M, Rovers MM, Roukema AJ, Drenth JP, Westert GP, van Laarhoven CJ. Persistent and de novo symptoms after cholecystectomy: a systematic review of cholecystectomy effectiveness. *Surg Endosc.* 2013 Mar;27(3):709-718.
- [25] Gridneva SV. Dysfunction of sphincter oddy after cholecystectomy: mechanisms of development and treatment tactics. *Suchasna gastroenterologiya.* 2015;3(83):122-127 (In Russ.)
- [26] Fisher M et al. Diarrhoea after laparoscopic cholecystectomy: incidence and main determinants. *ANZ J Surg.* 2008;78:482-486.
- [27] Kucheryavyy YuA, Selezneva EYa, Kotovskiy AE, et al. Condition after cholecystectomy: surgeon, therapist, patient. Report of the expert council on postcholecystectomy disorders. *Farmateka.* 2013;20:64-68 (In Russ.)
- [28] Kulkarni A. Sphincter of oddi dysfunction. *Pract Gastroenterol.* 2010;March:28-41.
- [29] Kalaitzakis E, Ambrose T, et al. Management of patients with biliary sphincter of oddi disorder without sphincter of oddi manometry. *BMC Gastroenterol.* 2010 oct 22;10:124. doi: 10.1186/1471-230X-10-124

- [30] Khuroo MS, et al. Efficacy of nifedipine therapy in patients with sphincter of oddi dysfunction: a prospective, double-blind, randomized, placebo-controlled, cross-over trial. *Br J Clin Pharmacol*. 1992;33:477-485.
- [31] Federal guidelines on the use of medicines (formular system). Issue XVIII. Moscow: Widox; 2017 (In Russ.)
- [32] Ryzhichkina AN, osipenko MF, Kholin SI. Chronic abdominal pain and irritable bowel syndrome. *Lechashchiy Vrach*. 2011;(2):30-34 (In Russ.)
- [33] Cash BD, Lacy BE, Schoenfeld PS. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. *Am J Gastroenterol*. 2017;112:365-374. doi: 10.1038/ajg.2016.542
- [34] Instructions for medical use of the preparation TrimedatR. Tablets 100 mg, 200 mg, of 20/03/2017 (In Russ.)
- [35] Khubutiya MSh, Popova TS, Saltanov AI, eds. Parenteral'noe i enteral'noe pitanie: Natsional'noe rukovodstvo [Parenteral and enteral nutrition: National guidelines]. Moscow: GEOTAR-Media; 2014. 800 p. (In Russ.) ISBN 978-5-9704-2853-5
- [36] FDA Safety Alerts for Human Medicinal Products. Viberzi (eluxadoline): Drug Safety Communication - Increased Risk of Serious Pancreatitis In Patients Without A Gallbladder. Posted 03/15/2017.
- [37] Lindner A, Seizer H, Claassen V, et al. Pharmacological properties of mebeverine, a smooth-muscle relaxant. *Arch Int Pharmacodyn*. 1963;145(3):378-395.
- [38] Evans P, Bak Y, Kellow J. Mebeverine altered small bowel motility in irritable bowel syndrome. *Aliment Pharmacol Ther*. 1996;5:787-793.
- [39] Den Hertog A, Van den Akker J. Modification of α_1 -receptor channels by mebeverine in smooth muscle cells of guinea pig taenia caeci. *Eur J Pharm*. 1987;138:367-374.
- [40] Stockis A, et al. Identification of mebeverine acid as the main circulating metabolite of mebeverine in man. *J Pharm Biomed Anal*. 2002;29:335-340.
- [41] Abdel-Hamid SM, Abdel-Hady SE, El-Shamy, et al. Formulation of an antispasmodic drug as a topical local anesthetic. *Int J Pharm*. 2006;326:107-118.